Analysis of Bcr-abl type transcript and its relationship with platelet count in Mexican patients with chronic myeloid leukemia
…, P Bahena-Reséndiz, M Vadillo-Buenfil… - Gaceta medica de …, 2003 - medigraphic.com
Problem. lt has been suggested that type of chimeric mRNA is associated with differences in
the clinical and hematologic characteristics of chronic myeloid Leukemia (CML). However, …
the clinical and hematologic characteristics of chronic myeloid Leukemia (CML). However, …
Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix.
…, J Pinski, M Vadillo-Buenfil… - Proceedings of the …, 1996 - National Acad Sciences
Antagonists of luteinizing hormone-releasing hormone (LH-RH), unlike the LH-RH agonists,
suppress gonadotropins and sex steroid secretion immediately after administration, without …
suppress gonadotropins and sex steroid secretion immediately after administration, without …
Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin …
…, RZ Gai, K Groot, M Vadillo-Buenfil… - European Journal of …, 1997 - Elsevier
The aim of this study was to test the antagonist of LH-RH (Cetrorelix), agonist [D-Trp 6 ]LH-RH
(triptorelin) and new bombesin antagonists RC-3940-II and RC-3950-II for their effect on …
(triptorelin) and new bombesin antagonists RC-3940-II and RC-3950-II for their effect on …
Análisis del tipo de transcrito bcr-abl y su relación con la cuenta plaquetaria en pacientes mexicanos con leucemia mieloide crónica
…, P Bahena-Reséndiz, M Vadillo-Buenfil… - Gaceta médica de …, 2003 - medigraphic.com
Problema: Se ha sugerido que el tipo de transcrito quimérico bcr-abl (b3a2 o b2a2) está
asociado con diferencias en las características clínicas y hematológicas de los pacientes con …
asociado con diferencias en las características clínicas y hematológicas de los pacientes con …
Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic …
D Gonzalez-Barcena, M Vadillo-Buenfil… - Urology, 1995 - Elsevier
Objectives. To assess the clinical response to luteinizing hormone-releasing hormone (LH-RH)
antagonist cetrorelix (SB-75) in patients with advanced carcinoma of the prostate and …
antagonist cetrorelix (SB-75) in patients with advanced carcinoma of the prostate and …
Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH …
…, K Groot, A Jungwirth, M Vadillo-Buenfil… - …, 1996 - academic.oup.com
Continuous exposure to LHRH or its agonistic analogs results in a reduction of LHRH receptor
sites and messenger RNA (mRNA) transcripts as well as in desensitization of the pituitary …
sites and messenger RNA (mRNA) transcripts as well as in desensitization of the pituitary …
Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs
…, JM Arencibia, K Groot, M Vadillo-Buenfil… - Journal of cancer …, 1999 - Springer
Reduction in receptors for epidermal growth factor (EGF) in cancers appears to be one of the
principal mechanisms through which peptide hormone analogs can inhibit tumor growth. In …
principal mechanisms through which peptide hormone analogs can inhibit tumor growth. In …
Inhibition of growth of human small cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH)
…, M Zarandi, M Vadillo-Buenfil - International …, 1996 - spandidos-publications.com
Insulin-like growth factors-I and-II (IGF-I and IGF-II) may be involved in the proliferation of
human lung carcinomas. The purpose of this study was to investigate the effects of two potent …
human lung carcinomas. The purpose of this study was to investigate the effects of two potent …
Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis.
…, J Vela-Ojeda, M Vadillo-Buenfil… - The Journal of …, 2003 - jrheum.org
OBJECTIVE: To evaluate the efficacy of pentoxifylline in the treatment of refractory nephrotic
syndrome secondary to lupus nephritis. METHODS: We studied 11 patients who met the …
syndrome secondary to lupus nephritis. METHODS: We studied 11 patients who met the …
[PDF][PDF] Leptina y su influencia en los principales padecimientos ginecoobstétricos
MV Buenfil, JV Ojeda, GG Rodríguez… - Ginecol Obstet …, 2005 - researchgate.net
La leptina es una hormona polipeptídica de origen adipocitario que quizá también se produce
en otros órganos y es capaz de regular múltiples funciones en todo el organismo, con …
en otros órganos y es capaz de regular múltiples funciones en todo el organismo, con …